UPDATE OF THE TRANSACTION ANNOUNCED ON NOVEMBER 25, 2025, FOR THE ACQUISITION OF THE MINORITY INTEREST IN THE SUBSIDIARY GROUPE TECHNOLOGIQUE KDA INC.
MWN-AI** Summary
On December 24, 2025, KDA Group Inc. (TSXV: KDA), a prominent provider of innovative technological solutions for healthcare, provided an update regarding its acquisition of a minority interest in its subsidiary, Groupe Technologique KDA Inc. (GTK). Initially announced on November 25, 2025, the transaction involves KDA acquiring a 20% interest in GTK from ERxpert Inc. In exchange for this stake, KDA will issue 35 million common shares.
The latest update highlights that KDA has received conditional approval from the TSX Venture Exchange (TSX-V) for this transaction as of December 18, 2025. This approval, however, is contingent upon the submission of specific documents and information as requested by the TSX-V, which must be filed by January 20, 2026. The final acceptance of the transaction will come following a satisfactory review of these materials.
KDA Group is noted for its focus on technological innovations and software solutions (SaaS) aimed at the healthcare sector. Its products are recognized for contributing to the ongoing digital transformation in healthcare, serving both Canadian and international markets. The acquisition of the additional stake in GTK aligns with KDA's strategic goals of enhancing their service offerings and market position.
The company emphasizes that forward-looking statements within their press release are based on estimates and assumptions which entail significant risks and uncertainties. As such, the outcomes of the acquisition and its impact on KDA's future performance remain subject to change. Further details about the corporation and its offerings can be accessed through their official website and on SEDAR+.
MWN-AI** Analysis
KDA Group Inc. (TSXV: KDA) has entered a significant transaction to acquire an additional 20% stake in its subsidiary, Groupe Technologique KDA Inc. (GTK), from ERxpert Inc. in a share transfer deal that includes the issuance of 35 million common shares of KDA. This acquisition is a strategic move to enhance KDA's hold on its innovative solutions within the healthcare technology sector.
The conditional approval from the TSX Venture Exchange (TSXV) received on December 18, 2025, signifies the market's acknowledgment of KDA's growth strategy. However, final approval remains contingent on the timely submission of necessary documentation by January 20, 2026. Investors should monitor this timeline closely, as any delays could impact market sentiment and stock volatility.
The acquisition appears to be a calculated approach for KDA to strengthen its competitive positioning in a rapidly evolving healthcare technology market. The move not only consolidates control over GTK’s technological advancements but also potentially increases revenue streams through improved product offerings and market penetration.
As KDA continues to innovate in digital solutions (SaaS) tailored for healthcare professionals, investors should assess the implications of this transaction on the company’s growth trajectory. The healthcare technology market is experiencing unprecedented transformation, driven by digitalization, and KDA's strategic alignments could yield significant returns.
Investors are advised to remain cautious, particularly regarding the potential risks highlighted in KDA's forward-looking statements. While the long-term prospects appear promising, short-term volatility may arise as market participants digest the news surrounding this share exchange. It is prudent to conduct thorough due diligence, considering both the growth potential and inherent risks associated with this acquisition before making investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Canada NewsWire
THETFORD MINES, QC, Dec. 24, 2025 /CNW/ - KDA Group Inc. (TSXV: KDA) ("KDA" or the "Corporation"), a leader in innovative technological solutions for healthcare professionals, announced on November 25, 2025, that it had entered into a share transfer agreement to acquire a twenty percent (20%) interest in the issued and outstanding shares of its subsidiary Groupe Technologique KDA inc. ("GTK") currently held by ERxpert Inc. (the "Transaction").
Under the terms of this agreement, ERxpert has agreed to transfer its shares in the GTK subsidiary to KDA in exchange for thirty-five million (35,000,000) common shares of KDA's share capital.
KDA announces that it has received conditional approval from the TSX Venture Exchange for the Transaction on December 18, 2025.
Final approval by the TSX Venture Exchange is conditional upon the filing of certain documents and information requested by the TSX Venture Exchange on or before January 20, 2026, and final acceptance by the TSX Venture Exchange will be issued after satisfactory review of the required documents and information.
ABOUT KDA GROUP
KDA Group is a leader in technological innovations and specialized software solutions (SaaS – Software as a Service) for the healthcare professionals' market. KDA is a corporation that offers high-quality products and has recognized and respected expertise among the various stakeholders in the pharmaceutical and medical sectors. The technology products developed by KDA aim, among other things, to accelerate the healthcare's digital transformation, and are available for the Canadian and international markets. Additional information about the Corporation is available at www.groupkda.com and on SEDAR+ at www.sedarplus.ca.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release from KDA Group contains forward-looking statements. Forward-looking statements are typically identified by the words assumption, goal, guidance, objective, outlook, strategy, target, and other similar expressions, or future or conditional verbs such as aim, anticipate, believe, predict, could, expect, intend, may, plan, seek, should, strive, and will. By their nature, forward-looking statements require us to make estimates and assumptions and express opinions based on current conditions and anticipated developments, as well as other factors that Management may deem appropriate under the circumstances. There is inherent uncertainty and significant risk in these estimates, assumptions, and opinions, particularly of a commercial, economic, and competitive nature, and they are therefore subject to change. KDA Group cannot guarantee that these estimates, assumptions, and opinions will prove to be accurate.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
SOURCE KDA Group Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/December2025/24/c4111.html
FAQ**
What is the strategic significance of KDA Group Inc. acquiring a 20% interest in Groupe Technologique KDA inc. (GTK) for KDA:CC's long-term growth plans within the healthcare technology sector?
How will the issuance of 35 million common shares to ERxpert Inc. affect KDA Group Inc.'s share structure and shareholder value in the short and long term?
What specific documents and information does KDA Group Inc. need to file with the TSX Venture Exchange by January 20, 2026, to secure final approval for the acquisition?
Can KDA Group Inc. provide insights on how the acquisition of GTK will enhance their current offerings and accelerate their market position in digital healthcare solutions?
**MWN-AI FAQ is based on asking OpenAI questions about Kda Group Inc. (TSXVC: KDA:CC).
NASDAQ: KDA:CC
KDA:CC Trading
-4.55% G/L:
$0.105 Last:
2,500 Volume:
$0.11 Open:
